-+ 0.00%
-+ 0.00%
-+ 0.00%

BioPorto activates the first US clinical site as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.

Barchart·08/18/2026 07:53:00
Listen to the news

August 18, 2026
Press Release

BioPorto activates the first US clinical site as part of the ProNephro AKI® U.S. Adult Urine NGAL Validation Study.

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.